TAUNS Laboratories, Inc. (197A.T)

TAUNS Laboratories, Inc. (197A.T) — VMCI valuation read

TAUNS Laboratories, Inc. sits at VMCI 56/100, with the Healthcare sector median at 50. That 6-point spread is the first thing to note on 197A.T: it tells the reader the composite is favorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on 197A.T are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on 197A.T: 197A.T trades at 20.0x earnings, 11% above the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp. The Risk read: net debt to EBITDA of 1.2x leaves covenant headroom, anchoring the bear scenario on a measurable balance-sheet metric.

197A.T rose 1.1% over the trailing 7 days, with a +4.8% read on a 30-day basis.